Allergan Plc announced that struck a global development and commercialisation agreement with AstraZeneca Plc regarding investigational antibiotic combination ATM-AVI. The fixed-dose combination of aztreonam and avibactam will be studied as treatment for serious infections triggered by metallo βlactamase MBL-producing Gram-negative pathogens. The terms of the deal give Allergan commercialisation rights in the US and Canada, with AstraZeneca holding them in all other countries.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
+1.73% | +0.97% |
1st Jan change | Capi. | |
---|---|---|
+0.97% | 63.66B | |
+62.11% | 856B | |
+38.95% | 631B | |
-4.15% | 359B | |
+15.47% | 325B | |
+9.10% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.96% | 177B | |
+2.28% | 165B |
- Stock Market
- Equities
- AGN Stock
- News Allergan plc
- Allergan Plc, AstraZeneca Plc Ink Collaboration Deal for Anti-Infective ATM-AVI